Skip to main content
Top
Published in: BMC Cancer 1/2020

01-12-2020 | Glioblastoma | Research article

Prognostic factors of patients with Gliomas – an analysis on 335 patients with Glioblastoma and other forms of Gliomas

Authors: Jianfeng Liang, Xiaomin Lv, Changyu Lu, Xun Ye, Xiaolin Chen, Jia Fu, Chenghua Luo, Yuanli Zhao

Published in: BMC Cancer | Issue 1/2020

Login to get access

Abstract

Background

The prognosis of glioma is poor, despite recent advances in diagnosis and treatment of the disease. It is important to investigate the clinical characteristics and prognostic factors of glioma so as to provide basis for treatment and management of patients.

Method

A total of 335 patients with glioma were included in this study. These patients were admitted to the medical center between November 2015 and December 2018. The clinical data, including demographic data, tumor characteristics, treatment strategy, expression pattern of tumor markers, and survival data, were retrospectively reviewed. Survival data were analyzed using Kaplan-Meier curves with log-rank test, while multivariate analysis Cox regression model was used to investigate risk factors for mortality.

Results

In this patient cohort, glioblastoma (40%), diffuse glioma (14.6%) and oligodendroglioma (9.6%) were the most common pathological types. The expression of Ki-67 was associated with several clinicopathological parameters (e.g. tumor type, grade, and number of lesions). In addition, Ki-67 correlated with the mortality within the first year of the post-treatment follow-up (P <  0.001). Kaplan-Maier analysis revealed that older patients (≥ 45 years) displayed worse prognosis than those aged under 45 years (P = 0.038). Dismal prognosis was also associated with clinical parameters, including high tumor grade, multiple lesions, and Karnofsky performance score (KPS). Multivariate analysis showed that low KPS (< 85) increased the risk of mortality by 2.3 folds with a 95% CI of 1.141 to 4.776 (P = 0.020). Low tumor grade (grade 1–2) oppositely reduced the mortality risk by 0.22 folds (95% CI, 0.065 to 0.763, P = 0.0168).

Conclusion

KPS and tumor grade were independent prognostic factors in patients with gliomas.
Literature
1.
go back to reference Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2:533–43.CrossRef Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2:533–43.CrossRef
2.
go back to reference Turner JD, Williamson R, Almefty KK, et al. The many roles of microRNAs in brain tumor biology. Neurosurg Focus. 2010;28:E3.CrossRef Turner JD, Williamson R, Almefty KK, et al. The many roles of microRNAs in brain tumor biology. Neurosurg Focus. 2010;28:E3.CrossRef
3.
go back to reference Thakkar JP, Dolecek TA, Horbinski C, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol, Biomark Prev : Publication Am Assoc Cancer Res, Cosponsored Am Soc Prev Oncol. 2014;23:1985–96.CrossRef Thakkar JP, Dolecek TA, Horbinski C, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol, Biomark Prev : Publication Am Assoc Cancer Res, Cosponsored Am Soc Prev Oncol. 2014;23:1985–96.CrossRef
4.
go back to reference Chen S, Tanaka S, Giannini C, et al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neuro-Oncol. 2013;112:267–75.CrossRef Chen S, Tanaka S, Giannini C, et al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neuro-Oncol. 2013;112:267–75.CrossRef
5.
go back to reference Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus Temozolomide vs Temozolomide alone for Glioblastoma: a randomized clinical trial. JAMA. 2015;314:2535–43.CrossRef Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus Temozolomide vs Temozolomide alone for Glioblastoma: a randomized clinical trial. JAMA. 2015;314:2535–43.CrossRef
6.
go back to reference Perry J, Zinman L, Chambers A, et al. The use of prophylactic anticonvulsants in patients with brain tumours-a systematic review. Curr Oncol. 2006;13:222–9.PubMedPubMedCentral Perry J, Zinman L, Chambers A, et al. The use of prophylactic anticonvulsants in patients with brain tumours-a systematic review. Curr Oncol. 2006;13:222–9.PubMedPubMedCentral
7.
go back to reference Schiff D, Lee EQ, Nayak L, et al. Medical management of brain tumors and the sequelae of treatment. Neuro-oncol. 2015;17:488–504.CrossRef Schiff D, Lee EQ, Nayak L, et al. Medical management of brain tumors and the sequelae of treatment. Neuro-oncol. 2015;17:488–504.CrossRef
8.
go back to reference Minniti G, Muni R, Lanzetta G, et al. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res. 2009;29:5171–84.PubMed Minniti G, Muni R, Lanzetta G, et al. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res. 2009;29:5171–84.PubMed
9.
go back to reference Hu X, Miao W, Zou Y, et al. Expression of p53, epidermal growth factor receptor, Ki-67 and O (6)-methylguanine-DNA methyltransferase in human gliomas. Oncol Lett. 2013;6:130–4.CrossRef Hu X, Miao W, Zou Y, et al. Expression of p53, epidermal growth factor receptor, Ki-67 and O (6)-methylguanine-DNA methyltransferase in human gliomas. Oncol Lett. 2013;6:130–4.CrossRef
10.
go back to reference Sarbu N, Oleaga L, Valduvieco I, et al. Increased signal intensity in FLAIR sequences in the resection cavity can predict progression and progression-free survival in gliomas. Neurocir. 2016;27:269–76.CrossRef Sarbu N, Oleaga L, Valduvieco I, et al. Increased signal intensity in FLAIR sequences in the resection cavity can predict progression and progression-free survival in gliomas. Neurocir. 2016;27:269–76.CrossRef
11.
go back to reference Danielson PD, Zottoli SJ, Corrodi JG, et al. Localization of choline acetyltransferase to somata of posterior lateral line efferents in the goldfish. Brain Res. 1988;448:158–61.CrossRef Danielson PD, Zottoli SJ, Corrodi JG, et al. Localization of choline acetyltransferase to somata of posterior lateral line efferents in the goldfish. Brain Res. 1988;448:158–61.CrossRef
12.
go back to reference Dahlrot RH. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas. Dan Med J. 2014;61:B4944.PubMed Dahlrot RH. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas. Dan Med J. 2014;61:B4944.PubMed
13.
go back to reference Ampie L, Choy W, Lamano JB, et al. Prognostic factors for recurrence and complications in the surgical management of primary chordoid gliomas: a systematic review of literature. Clin Neurol Neurosurg. 2015;138:129–36.CrossRef Ampie L, Choy W, Lamano JB, et al. Prognostic factors for recurrence and complications in the surgical management of primary chordoid gliomas: a systematic review of literature. Clin Neurol Neurosurg. 2015;138:129–36.CrossRef
14.
go back to reference Qian Z, Li Y, Fan X, et al. Prognostic value of a microRNA signature as a novel biomarker in patients with lower-grade gliomas. J Neuro-Oncol. 2018;137:127–37.CrossRef Qian Z, Li Y, Fan X, et al. Prognostic value of a microRNA signature as a novel biomarker in patients with lower-grade gliomas. J Neuro-Oncol. 2018;137:127–37.CrossRef
15.
go back to reference Huang Q, Wang C, Hou Z, et al. Serum microRNA-376 family as diagnostic and prognostic markers in human gliomas. Cancer Biomark : Sect A Dis Markers. 2017;19:137–44.CrossRef Huang Q, Wang C, Hou Z, et al. Serum microRNA-376 family as diagnostic and prognostic markers in human gliomas. Cancer Biomark : Sect A Dis Markers. 2017;19:137–44.CrossRef
16.
go back to reference Vuong HG, Altibi AMA, Duong UNP, et al. BRAF mutation is associated with an improved survival in Glioma-a systematic review and meta-analysis. Mol Neurobiol. 2018;55:3718–24.PubMed Vuong HG, Altibi AMA, Duong UNP, et al. BRAF mutation is associated with an improved survival in Glioma-a systematic review and meta-analysis. Mol Neurobiol. 2018;55:3718–24.PubMed
17.
go back to reference Bigner DD, Brown MT, Friedman AH, et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol : Official J Am Soc Clin Oncol. 1998;16:2202–12.CrossRef Bigner DD, Brown MT, Friedman AH, et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol : Official J Am Soc Clin Oncol. 1998;16:2202–12.CrossRef
18.
go back to reference Yang F, Yang P, Zhang C, et al. Stratification according to recursive partitioning analysis predicts outcome in newly diagnosed glioblastomas. Oncotarget. 2017;8:42974–82.PubMedPubMedCentral Yang F, Yang P, Zhang C, et al. Stratification according to recursive partitioning analysis predicts outcome in newly diagnosed glioblastomas. Oncotarget. 2017;8:42974–82.PubMedPubMedCentral
Metadata
Title
Prognostic factors of patients with Gliomas – an analysis on 335 patients with Glioblastoma and other forms of Gliomas
Authors
Jianfeng Liang
Xiaomin Lv
Changyu Lu
Xun Ye
Xiaolin Chen
Jia Fu
Chenghua Luo
Yuanli Zhao
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2020
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-6511-6

Other articles of this Issue 1/2020

BMC Cancer 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine